CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Elutia Q3 revenue rises on cardiovascular growth

By Reuters News


Overview

  • Drug delivery firm's Q3 revenue rose 20% yr/yr, driven by cardiovascular business growth

  • Company added $26 mln in capital without equity offering, funding operations through 2028

  • Net loss narrowed to $1.3 mln from $3.9 mln, helped by income from discontinued operations


Outlook

  • Elutia plans to submit NXT-41x to FDA in Q4 2026

  • Company anticipates FDA clearance for NXT-41x in 1H 2027

  • Elutia expects NXT-41x soft launch in 2H 2027 and full commercial launch in 2028


Result Drivers

  • CARDIOVASCULAR GROWTH - Co said cardiovascular business revenue rose 20% yr/yr in Q3, supporting overall sales growth

  • HIGHER R&D SPENDING - Operating expenses increased due to $1.9 mln rise in research and development for NXT-41 and NXT-41x programs

  • DISCONTINUED OPERATIONS - $5.2 mln in income from discontinued operations helped narrow the quarterly net loss


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.14 mln

$1 mln (1 Analyst)

Q3 Net Loss

$1.29 mln

Q3 Gross Profit

$702,000

Q3 Income From Operations

-$6.90 mln

Q3 Operating Expenses

$7.60 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Elutia Inc is $5.00, about 558.2% above its November 4 closing price of $0.76


Reuters Recommended Reads

  • Nov 4 - Cytokinetics Q3 net loss narrows as net product revenue rises

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

  • Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.